Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.
- 10-Q report · filed Nov 9, 2026
- Editas Medicine received approval in October 2026 to initiate the Strive trial of EDIT-401 in Australia, with dosing on track for 2026. Net loss was $66.6 million for the nine months ended September 30, 2026, versus $154.4 million in 2025.
The audio replay and transcript follow the call.